5 Minutes with Maria Gonzalez
20 May 2016
This International Clinical Trials Day (20th May) we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future. We've sat down with MIA's Clinical Trials Manager, Maria Gonzalez to discuss.
What does a Clinical Trials Manager do and how did you get here?
In my role I work with a team of highly dedicated and caring trial co-ordinators who are responsible for looking after our trial patients. I completed a degree in nursing at The University of Sydney and worked at Royal Prince Alfred Hospital before deciding to work in clinical trials in the hope that I may contribute to life-saving research. I have been at MIA for 6 years now.
What are clinical trials so important?
Clinical trials provide patients with access to unavailable new treatments and are also the vital step in making discoveries that will enable us to find a cure for melanoma. Clinical trials are also an opportunity for patients to receive very specialised care from clinical trial co-ordinators who are available at every step along the way to support patients and their families.
What do you find most rewarding about your work?
As a nurse I am most rewarded by making a difference in the lives of those suffering with cancer. It is a privilege to be part of a patient support network at MIA and also wonderful to share in the good news when a trial treatment is successful. Although we have made significant progress and the future is positive, it is important we keep working together to find the cure.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.